• 1. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

Methyl 3-bromo-4-(trifluoromethyl)benzoate (CAS No. 455941-82-9): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 3-bromo-4-(trifluoromethyl)benzoate, identified by its CAS number 455941-82-9, is a highly valuable intermediate in the realm of pharmaceutical synthesis. This compound, characterized by its brominated and trifluoromethyl-substituted benzene ring, has garnered significant attention due to its versatile applications in the development of novel therapeutic agents. The presence of both bromine and trifluoromethyl groups imparts unique reactivity and electronic properties, making it a preferred choice for synthetic chemists aiming to modulate bioactivity and metabolic stability in drug candidates.

The structural motif of Methyl 3-bromo-4-(trifluoromethyl)benzoate is particularly noteworthy for its potential in constructing complex molecular frameworks. The bromine atom at the 3-position provides a handle for further functionalization via cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings, which are pivotal in the synthesis of biaryl structures commonly found in active pharmaceutical ingredients (APIs). Concurrently, the trifluoromethyl group at the 4-position enhances lipophilicity and metabolic resistance, attributes that are critically evaluated during drug design to improve pharmacokinetic profiles.

In recent years, the pharmaceutical industry has witnessed a surge in the exploration of heterocyclic compounds incorporating halogenated aromatic rings. Among these, benzoate derivatives have emerged as a prominent class due to their demonstrated efficacy across various therapeutic domains. Methyl 3-bromo-4-(trifluoromethyl)benzoate stands out as a cornerstone compound in this landscape, serving as a precursor for synthesizing kinase inhibitors, antiviral agents, and anti-inflammatory drugs. Its incorporation into drug molecules has been linked to improved binding affinity and target specificity, underscoring its importance in medicinal chemistry.

The utility of CAS No. 455941-82-9 extends beyond its role as a synthetic intermediate; it also finds application in material science and agrochemical research. The electron-withdrawing nature of the trifluoromethyl group influences the electronic properties of materials derived from this compound, making it relevant for developing advanced polymers and liquid crystals. Additionally, its structural features contribute to the design of novel agrochemicals with enhanced biological activity against pests and pathogens.

Advancements in synthetic methodologies have further amplified the significance of Methyl 3-bromo-4-(trifluoromethyl)benzoate. Modern techniques such as flow chemistry and microwave-assisted synthesis have enabled more efficient and scalable production processes for this compound. These innovations not only reduce manufacturing costs but also minimize waste generation, aligning with the growing emphasis on sustainable chemistry practices. The ability to produce high-purity batches of this intermediate under controlled conditions ensures reliability for downstream applications in drug development.

The pharmacological relevance of compounds like Methyl 3-bromo-4-(trifluoromethyl)benzoate is underscored by ongoing clinical trials investigating novel therapeutics derived from related scaffolds. For instance, researchers are exploring derivatives of this compound as potential treatments for neurological disorders, where modulation of neurotransmitter activity is key. Preclinical studies have demonstrated promising results in animal models, highlighting the need for robust supply chains of key intermediates such as this one to support further development.

In conclusion, Methyl 3-bromo-4-(trifluoromethyl)benzoate (CAS No. 455941-82-9) represents a critical component in contemporary pharmaceutical synthesis. Its unique structural features enable diverse applications across multiple industries, from drug development to advanced materials. As research continues to uncover new therapeutic possibilities and sustainable synthetic routes, this compound will undoubtedly remain integral to innovation in chemical sciences.

• 107317-58-8(Methyl 4-bromo-3-(trifluoromethyl)benzoate)
• 1214323-47-3(methyl 3-bromo-2-(trifluoromethyl)benzoate)
• 463355-64-8(Ethyl 4-bromo-3-(trifluoromethyl)benzoate)
• 1214386-97-6(Ethyl 3-bromo-4-(trifluoromethyl)benzoate)
• 581813-17-4(3-Bromo-4-(trifluoromethyl)benzoic acid)
• 187331-46-0(Methyl 3-bromo-5-(trifluoromethyl)benzoate)
• 886860-76-0(BENZOIC ACID, 4-BROMO-3-(DIFLUOROMETHYL)-, METHYL ESTER)
• 1026355-57-6(Methyl 2-bromo-5-(trifluoromethyl)benzoate)
• 1214362-28-3(METHYL 2-BROMO-3-(TRIFLUOROMETHYL)BENZOATE)
• 1214334-90-3(Methyl 2-bromo-4-(trifluoromethyl)benzoate)